BioSpace News Archive

-- Investment brings total funding to $9.5 million -- Financing will support preclinical development of its platform and investigational therapy for kidney and other age-related diseases

Erasca, a clinical-stage precision oncology company whose mission is to erase cancer and that is singularly focused on advancing therapies for patients with RAS/MAPK pathway-driven cancers, announced the expansion of its leadership team with key hires in finance, business development, operations, legal, regulatory, manufacturing, clinical pharmacology and data science.

Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, announced the pricing of its upsized initial public offering of 10,200,000 shares of its common stock at an initial public offering price of $22.00 per share.

EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization

The viral vector and plasmid DNA s are being increasingly used in clinical trials as they provide the highest accuracy in delivering the gene to the region of interest.

At present, urethral stricture infection is a noteworthy issue among men. Numerous treatment methodology are accessible for urethral strictures.

Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance[i] of approximately $92 million as of March 31, 2021, compared to approximately $115 million as of March 31, 2020

Rheos Medicines, a biopharmaceutical company transforming the treatment of autoimmune disease through its metabolic precision medicine engine (MetPM) announced that Barbara S. Fox , Ph.D., Chief Executive Officer of Rheos Medicines, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12:30 p.m.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He , Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany